Lung health probiotic supplement works against key inflammatory markers, new preclinical data show

Photo from ResBiotic Nutrition Inc.

Microbiome-nutrition company ResBiotic Nutrition Inc. (Birmingham, AL) recently presented new preclinical data showing that its lung health supplement acts against key inflammatory markers. The product, ResB Lung Support, is a probiotic and herbal dietary supplement.

ResB contains the following probiotic strains: Lactiplantibacillus plantarum RSB11, Lactobacillus acidophilus RSB12, and Lacticaseibacillus rhamnosus RSB13. Its botanical ingredients include vasaka (Adhatoda vasica) leaf extract, holy basil (Ocimum sanctum) leaf extract, and turmeric (Curcuma longa) root extract.

Data from the preclinical in vitro study was presented at May’s Digestive Disease Week 2022 held in San Diego, CA. In the study, researchers sought to examine whether ResB oral supplementation would help reduce inflammation in the lungs and reduce damage resulting from bacterial imbalance (dysbiosis). They found that ResB was associated with a decrease in MMP-9 inflammatory pathway activity. This activity is associated with tissue damage and neutrophilic inflammation. Not only that, “In mouse models of dysbiosis and lung tissue damage, oral ResB administration leads to improved lung structure and reduced neutrophilic activity and inflammatory cells in the blood,” the company said in a press release.

“These important findings reaffirm the role of our proprietary blend of probiotic strains and bioactive botanical extracts in targeting the gut-lung axis,” said the company’s founder and CEO Vivek Lal, MD, FAAP, in a press release. The company says it is conducting human clinical trials, including ongoing trials on the effects of ResB in healthy people, smokers, and people with asthma.